Home Cart Sign in  
Chemical Structure| 724741-75-7 Chemical Structure| 724741-75-7

Structure of STF-31
CAS No.: 724741-75-7

Chemical Structure| 724741-75-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

STF-31 is a glucose transporter 1 (GLUT1) inhibitor with IC50 of 1 μM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of STF-31

CAS No. :724741-75-7
Formula : C23H25N3O3S
M.W : 423.53
SMILES Code : O=C(NC1=CC=CN=C1)C2=CC=C(CNS(=O)(C3=CC=C(C(C)(C)C)C=C3)=O)C=C2
MDL No. :MFCD04153828
InChI Key :NGQPRVWTFNBUHA-UHFFFAOYSA-N
Pubchem ID :984333

Safety of STF-31

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P301+P312+P330

Isoform Comparison

Biological Activity

Target
  • GLUT1

In Vitro:

Cell Line
Concentration Treated Time Description References
ACHN cells (VHL shRNA) 5 μM 10 days Evaluate the toxicity of STF-31 to VHL shRNA cells, results showed STF-31 significantly reduced the viability of ACHN cells. PMC3683134
RCC4/VHL cells (VHL wild-type) 5 μM 10 days Evaluate the toxicity of STF-31 to VHL wild-type cells, results showed STF-31 had minimal effect on the viability of RCC4/VHL cells. PMC3683134
Human microvascular endothelial cells (HMEC) 100 µM 16 hours To test the effect of STF-31 on tube formation in HMECs, results showed that STF-31 failed to inhibit tube formation. PMC7145862
Human embryonic stem cells (hESCs) 2.5 μM 24-72 hours Evaluate the toxic effects of STF-31 on hESCs, results showed STF-31 significantly reduced cell viability within 72 hours PMC4414215
Human induced pluripotent stem cells (hiPSCs) 2.5 μM 24-72 hours Evaluate the toxic effects of STF-31 on hiPSCs, results showed STF-31 significantly reduced cell viability to 10% within 72 hours PMC4414215
RCC4 cells (VHL-deficient) 5 μM 4 days Evaluate the toxicity of STF-31 to VHL-deficient cells, results showed STF-31 significantly reduced the viability of RCC4 cells. PMC3683134
GLC-36 0.1, 1.0, 5.0, 10.0, 50.0, 100.0 µM 4 days GLC-36 cells showed partial resistance to STF-31 at intermediate concentrations but were still affected at high concentrations. PMC10001048
GLC-2 0.1, 1.0, 5.0, 10.0, 50.0, 100.0 µM 4 days STF-31 treatment significantly reduced cell numbers in GLC-2 cells, even at low concentrations of 0.1 µM. PMC10001048
QPG-1 0.1, 1.0, 5.0, 10.0, 50.0, 100.0 µM 4 days STF-31 treatment significantly reduced cell numbers in QPG-1 cells, even at low concentrations of 0.1 µM. PMC10001048
BON-1 0.1, 1.0, 5.0, 10.0, 50.0, 100.0 µM 4 days STF-31 treatment significantly reduced cell numbers in GLC-2 and QPG-1 cells, even at low concentrations of 0.1 µM. GLC-36 cells showed partial resistance at intermediate concentrations, while Bon-1 cells exhibited high resistance. PMC10001048
N27 cells 0.5 μM 48 hours Inhibition of GLUT-like glucose transport significantly reduced PQ-induced cell death PMC5173445
Human induced pluripotent stem cells (hiPSCs) 2.5 μM 48-72 hours Evaluate the toxic effect of STF-31 on hiPSCs, showing 80% cell death within 48 hours and almost complete death within 72 hours PMC4110789
Human embryonic stem cells (hESCs) 2.5 μM 48-72 hours Evaluate the toxic effect of STF-31 on hESCs, showing 80% cell death within 48 hours and almost complete death within 72 hours PMC4110789
HCT116 cells 200 nM 72 hours To evaluate the growth inhibitory effect of STF-31 analogue compound 146 on HCT116 cells, results showed that compound 146 effectively inhibited cell growth. PMC4201331
HESC-derived cardiomyocytes (hESC-CMs) 2.5 μM 72 hours Evaluate the effect of STF-31 on hESC-CMs, showing no adverse effects PMC4110789
Human fibroblasts (hFibs) 2.5 μM 72 hours Evaluate the effect of STF-31 on hFibs, showing no adverse effects PMC4110789
Human mesenchymal stem cells (hMSCs) 2.5 μM 72 hours Evaluate the effect of STF-31 on hMSCs, showing no adverse effects PMC4110789

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice 786-O and ACHN xenograft models Intraperitoneal injection 11.6 mg/kg (first 3 days), followed by 7.8 mg/kg (7-9 days) Once or twice daily for 10-14 days Evaluate the antitumor effect of STF-31 analog in vivo, results showed STF-31 significantly delayed tumor growth without toxicity to normal tissues. PMC3683134

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.36mL

0.47mL

0.24mL

11.81mL

2.36mL

1.18mL

23.61mL

4.72mL

2.36mL

References

 

Historical Records

Categories